Since LOC101927668 expression remained consistent in CRC patients regardless of KRAS and BRAF mutation status (Fig. S13A), we investigated several transcription factors, including MACC1, E2F3, and SIX2, known for their oncogenic roles in CRC tumorigenesis [66–68]. This evidence concerns the gene KRAS and colorectal carcinoma.